Repairon Immuno uses a licensed iPSC line and a GMP‑compliant differentiation platform to produce off‑the‑shelf, gene‑edited T‑cell products for CAR‑T and in‑vivo CAR therapies. The standardized process delivers homogeneous cells at scale, lowering manufacturing costs and improving batch consistency for biopharma developers.
Funding
Funding not disclosed
Founders
Product
Problem
Manufacturing CAR‑T and emerging in‑vivo CAR therapies currently relies on patient‑specific processes, which are expensive, time‑consuming, and produce variable product quality.
Solution
Repairon Immuno leverages a licensed, well‑characterized induced pluripotent stem cell (iPSC) line combined with a proprietary, GMP‑compliant differentiation platform to generate off‑the‑shelf immune cells. By applying precise gene‑editing designs to the iPSC line before differentiation, the company produces homogeneous T‑cell products at scale. This standardized approach reduces manufacturing costs, shortens production timelines, and improves batch‑to‑batch consistency, enabling more reliable and accessible CAR‑T and in‑vivo CAR therapies.
Target Audience
Primary customers are biopharmaceutical companies and clinical developers developing CAR‑T or in‑vivo CAR immunotherapies that require scalable, consistent, and cost‑effective cell manufacturing.
Features
- Licensed, clinically validated iPSC line serving as a renewable, unlimited source for immune cell production
- Proprietary gene‑editing of iPSCs to embed therapeutic designs prior to differentiation
- Scalable GMP‑compliant differentiation process that yields large quantities of identical T‑cell products
- Off‑the‑shelf cell drug products with high homogeneity and controlled safety profiles
- Platform capable of supporting both conventional CAR‑T and next‑generation in‑vivo CAR modalities